Abstract
OP 2.3 – 00117 The EZH2 inhibitor Tazemetostat increases MHC I antigen presentation in vitro and in vivo, enhancing antiviral activities of HIV-specific CTLs
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have